# Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms

> **NCT02626572** · PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 500 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** S47445 5mg
- **DRUG:** S47445 15mg
- **DRUG:** S47445 50mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02626572
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02626572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02626572, "Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02626572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*